Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine (azacitidine)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Dr. Richard Schlenk, University of Ulm
ClinicalTrials.gov Identifier:
NCT01180322
First received: August 2, 2010
Last updated: August 30, 2013
Last verified: August 2013

August 2, 2010
August 30, 2013
November 2010
June 2012   (final data collection date for primary outcome measure)
Rates of complete remission (CR) after induction therapy [ Time Frame: 56 days ] [ Designated as safety issue: No ]
To evaluate the impact of sequential or concurrent addition of 5-azacytidine to intensive induction chemotherapy with idarubicin and etoposide on the CR rate
Same as current
Complete list of historical versions of study NCT01180322 on ClinicalTrials.gov Archive Site
  • Event-free survival [ Time Frame: after two years of follow-up ] [ Designated as safety issue: No ]
  • Relapse-free survival [ Time Frame: after two years of follow-up ] [ Designated as safety issue: No ]
  • overall survival [ Time Frame: after two years of follow-up ] [ Designated as safety issue: No ]
  • days in hospital during each cycle and during the whole intervention [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Rate of early deaths or hypoplastic deaths (ED/HD) [ Time Frame: 56 days ] [ Designated as safety issue: Yes ]
  • type, frequency, severity (graded using the National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] Version 3.0), timing and relatedness of non-hematological toxicity observed during different treatment cycles [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
  • quality of life [ Time Frame: at the end of therapy (in average 6 months) and once a year in the follow-up ] [ Designated as safety issue: No ]
    quality of life assessed by the EORTC Quality of Life Core Questionnaire (QLQ-C30), supplemented by information on self-assessed concomitant diseases, late treatment effects, and demographics according to Messerer et al [35].
  • duration of leukopenia after each consolidation cycle [ Time Frame: 42 days ] [ Designated as safety issue: No ]
  • duration of neutropenia after each consolidation cycle [ Time Frame: 42 days ] [ Designated as safety issue: No ]
  • duration of thrombocytopenia after each consolidation cycle [ Time Frame: 42 days ] [ Designated as safety issue: No ]
  • duration of leukopenia after each induction cycle [ Time Frame: 28 days ] [ Designated as safety issue: Yes ]
  • duration of neutropenia after each induction cycle [ Time Frame: 28 days ] [ Designated as safety issue: Yes ]
  • duration of thrombocytopenia after each induction cycle [ Time Frame: 28 days ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine
Randomized Phase-II Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine

This is a randomized phase II, four-arm, open-label, multi-center study in adult patients with acute myeloid leukemia (AML) as defined in inclusion/exclusion criteria.

The primary efficacy objective is to evaluate the impact of sequential or concurrent addition of 5-azacytidine to intensive induction chemotherapy with idarubicin and etoposide on the complete remission (CR) rate

Sample size: 336 patients

The treatment duration of an individual patient randomized into one of the three experimental arms (Arm B, C, D) (in case of application of induction, consolidation and maintenance therapy with Azacitidine) is about 30 months.

The treatment duration for patients randomized into the standard arm of the study (Arm A) is about 7 months (in case of application of induction, consolidation and 2-yrs observation as maintenance (without treatment with Azacitidine)).

In case of induction followed by consolidation with allogeneic Stem cell transplantation (SCT) the treatment duration per patient is about 6 months.

Every patient will be followed until month 54 after inclusion into the study. Duration of the study for an individual patient including treatment (induction, consolidation [chemotherapy or allogeneic SCT], maintenance [experimental arm with Azacitidine or observation]) and follow-up period: 54 months

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Acute Myeloid Leukemia (AML)
  • Drug: Cytarabine

    Induction therapy:100 mg/m2/day by continuous intravenous (IV) infusion on days 1-7 (total dose 700 mg/m2)

    Consolidation therapy:

    Younger adults (18 to 65 years): 3 g/m2/day by IV infusion over 3 hours every 12 hours on days 1, 2, and 3 (total dose 18 g/m2).

    Elderly patients (>65 years): 1 g/m2/day by IV infusion over 3 hours every 12 hours on days 1, 2, and 3 (total dose 6 g/m2).

  • Drug: Idarubicin

    First induction therapy:

    Arm A, C, D:

    12 mg/m2/day by IV push on days 1,3,5 (total dose 36 mg/m2). For elderly (>65 yrs) patients only two doses of idarubicin are foreseen on days 1+3.

    Arm B:

    12 mg/m2/day by IV push on days 6, 8 10 (total dose 36 mg/m2). For elderly (>65 yrs) patients only two doses of idarubicin are foreseen on days 6+8.

    Second induction therapy:

    Arm A, C, D:

    12 mg/m2/day by IV push on days 1 and 3 (total dose 24 mg/m2; for all age groups)

    Arm B:

    12 mg/m2/day by IV push on days 6 and 8 (total dose 24 mg/m2; for all age groups).

  • Drug: Etoposide

    Induction therapy:

    Arm A, C, D:

    100 mg/m²/day by 1-hour IV infusion on days 1,2,3 (total dose 300 mg/m2). On days 1 and 3 start after idarubicin push. For elderly (>65 yrs) patients only two doses of etoposide are foreseen on days 1+3.

    Arm B:

    100 mg/m²/day by 1-hour IV infusion on days 6,7,8 (total dose 300 mg/m2). On days 6 and 8 start after idarubicin push. For elderly (>65 yrs) patients only two doses of etoposide are foreseen on days 6+8.

  • Drug: Azacitidine

    Induction therapy:

    Arm B and C:

    100 mg/m2/day by subcutaneous (SC) injection or 15-minute IV infusion on day 1 to day 5 (total dose 500 mg/m2). Azacitidine is always given prior to idarubicin and etoposide.

    Arm D:

    100 mg/m2/day by SC injection or 15-minute IV infusion on days 4-8 (total dose 500 mg/m2). Azacitidine is always given prior to idarubicin and etoposide.

    Maintenance therapy:

    Arm B, C, D:

    50 mg/m2/day by SC injection on days 1-5 (total dose 250 mg/m2) every 4 weeks. (Maintenance therapy is scheduled for a total duration of 2 years in patients with continuous CR)

  • Drug: Lenograstim

    Consolidation therapy:

    subcutaneously daily beginning on day 10 until neutrophil count > 0.5 x 109/l.

  • Active Comparator: Arm A
    Standard Therapy
    Interventions:
    • Drug: Cytarabine
    • Drug: Idarubicin
    • Drug: Etoposide
    • Drug: Lenograstim
  • Experimental: Arm B
    Investigational Therapy "Azacitidine Prior"
    Interventions:
    • Drug: Cytarabine
    • Drug: Idarubicin
    • Drug: Etoposide
    • Drug: Azacitidine
    • Drug: Lenograstim
  • Experimental: Arm C
    Investigational Therapy "Azacitidine Concurrent"
    Interventions:
    • Drug: Cytarabine
    • Drug: Idarubicin
    • Drug: Etoposide
    • Drug: Azacitidine
    • Drug: Lenograstim
  • Experimental: Arm D
    Investigational Therapy "Azacitidine After"
    Interventions:
    • Drug: Cytarabine
    • Drug: Idarubicin
    • Drug: Etoposide
    • Drug: Azacitidine
    • Drug: Lenograstim
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
336
October 2016
June 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with suspected diagnosis of acute myeloid leukemia or related precursor neoplasm, or acute leukemia of ambiguous lineage (classified according to the World Health Organization (WHO) classification)
  • Patients considered eligible for intensive chemotherapy
  • WHO performance status of ≤ 2
  • Age ≥ 18 years. There is no upper age limit.
  • No prior chemotherapy for leukemia except hydroxyurea to control hyperleukocytosis
  • Non-pregnant and non-nursing. Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test within a sensitivity of at least 25 mIU/mL within 72 hours prior to registration. "Women of childbearing potential" is defined as a sexually active mature woman who has not undergone a hysterectomy or who has had menses at any time in the preceding 24 consecutive months.
  • Female patients in the reproductive age and male patients must agree to avoid getting pregnant or to father a child while on therapy and for 3 month after the last dose of chemotherapy.
  • Women of child-bearing potential must either commit to continued abstinence from heterosexual intercourse or begin one acceptable method of birth control (IUD, tubal ligation, or partner's vasectomy). Hormonal contraception is an inadequate method of birth control.
  • Men must use a latex condom during any sexual contact with women of childbearing potential, even if they have undergone a successful vasectomy. (while on therapy and for 3 month after the last dose of chemotherapy)
  • Signed written informed consent.

Exclusion Criteria:

-AML with other recurrent genetic abnormalities (according to WHO 2008): AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 AML with t(15;17)(q22;q12); PML-RARA (or variant translocations with other RARA gene fusions)

  • AML with NPM1 mutation
  • AML with FLT3 mutation
  • Performance status WHO >2
  • Patients with ejection fraction < 50% by Multi Gated Acquisition Scan (MUGA) or echocardiogram (ECHO scan) within 14 days of day 1
  • Organ insufficiency (creatinine >1.5x upper normal serum level; bilirubin, AST or ALP >2.5x upper normal serum level, not attributable to AML; heart failure NYHA III/IV; severe obstructive or restrictive ventilation disorder)
  • Uncontrolled infection
  • Severe neurological or psychiatric disorder interfering with ability of giving an informed consent
  • Patients with a "currently active" second malignancy other than non-melanoma skin cancers. Patients are not considered to have a "currently active" malignancy if they have completed therapy and are considered by their physician to be at less than 30% risk of relapse within one year.
  • Known positive for Human immunodeficiency virus (HIV)
  • Bleeding disorder independent of leukemia
  • No consent for registration, storage and processing of the individual disease-characteristics and course as well as information of the family physician and/or other physicians involved in the treatment of the patient about study participation.
  • No consent for biobanking.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Austria,   Germany
 
NCT01180322
AMLSG 12-09
Yes
Dr. Richard Schlenk, University of Ulm
University of Ulm
Not Provided
Principal Investigator: Richard F Schlenk, MD University Hospital of Ulm
University of Ulm
August 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP